27.4000.51% ( -0.140 )
Closed: Nov 20, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is 38.72, above the reasonable range, cheaper than 8.59% of the time in the past 5 years, and the industry ranks 45/255, the industry Median -0.87.
38.72xP/E
$27.40Stock price
$0.71Earnings per share
38.72xP/E
Stock price$27.40Earnings per share$0.71
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 14.39x
- Typical range
- 8.38x–20.00x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03468102136
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
JNJUSJohnson & Johnson | 40.45x | 33.62% | $651.11B |
PFEUSPfizer | 38.72x | 13.37% | $156.18B |
MKKGYUSMerck | 31.43x | -- | $69.28B |
RDYUSDr Reddys Laboratories | 41.48x | 10.51% | $12.40B |
CORTUSCorcept Therap | 43.15x | 175.85% | $6.88B |
ETONUSEton Pharmaceuticals | 35.20x | 1,282.35% | $1.76B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
